Clinical comprehensive evaluation of 5 kinds of biologic targeted drugs in the treatment of severe eosinophilic asthma

LIAN Yufei; XIONG Shujuan; LIU Hongtao; ZHAO Haijing; WU Huizhen

doi:10.6039/j.issn.1001-0408.2026.13.17

您当前的位置：

首页 >

文章列表页 >

Clinical comprehensive evaluation of 5 kinds of biologic targeted drugs in the treatment of severe eosinophilic asthma

更新时间：2026-07-10

- Clinical comprehensive evaluation of 5 kinds of biologic targeted drugs in the treatment of severe eosinophilic asthma
- ZHONGGUO YAOFANG Vol. 37, Issue 13, Pages: 1755-1761(2026)
- 作者机构：
  
  1.河北省人民医院药学部，石家庄　050051
  2.河北省临床药学重点实验室，石家庄　050051
  3.河北医科大学第一医院药学部，石家庄　050031
  4.河北省人民医院科研处，石家庄　050051
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2026.13.17
  CLC： R979.1
- Received：12 February 2026，
  
  Revised：2026-06-15，
  
  Accepted：15 June 2026，
  
  Published：15 July 2026
- 稿件说明：
移动端阅览
连玉菲,熊淑娟,刘洪涛,等.5种生物靶向药物治疗重度嗜酸性粒细胞性哮喘的临床综合评价[J].中国药房,2026,37(13):1755-1761.

LIAN Yufei,XIONG Shujuan,LIU Hongtao,et al.Clinical comprehensive evaluation of 5 kinds of biologic targeted drugs in the treatment of severe eosinophilic asthma[J].ZHONGGUO YAOFANG,2026,37(13):1755-1761.
连玉菲,熊淑娟,刘洪涛,等.5种生物靶向药物治疗重度嗜酸性粒细胞性哮喘的临床综合评价[J].中国药房,2026,37(13):1755-1761. DOI： 10.6039/j.issn.1001-0408.2026.13.17.

LIAN Yufei,XIONG Shujuan,LIU Hongtao,et al.Clinical comprehensive evaluation of 5 kinds of biologic targeted drugs in the treatment of severe eosinophilic asthma[J].ZHONGGUO YAOFANG,2026,37(13):1755-1761. DOI： 10.6039/j.issn.1001-0408.2026.13.17.

摘要

目的

对治疗重度嗜酸性粒细胞性哮喘（SEA）的5种生物靶向药物进行临床综合评价，为医疗机构合理遴选该类药物提供客观依据。

方法

采用《中国医疗机构药品评价与遴选快速指南（第三版）》中的评价方法，对我国已上市的治疗SEA的5种生物靶向药物（奥马珠单抗、美泊利珠单抗、本瑞利珠单抗、度普利尤单抗、特泽利尤单抗）的有效性、安全性、药学特性、经济性及其他属性5个维度进行量化评分，并根据评分结果划分推荐级别。

结果

综合评分结果显示：美泊利珠单抗81.29分，为强推荐品种；本瑞利珠单抗78.05分，度普利尤单抗77.84分，奥马珠单抗70.14分，均为可推荐品种；特泽利尤单抗67.77分，为弱推荐品种。

结论

美泊利珠单抗在嗜酸性粒细胞清除率上表现优异、可及性好，且更经济，在SEA治疗中更具遴选优势；奥马珠单抗在免疫球蛋白E增高型SEA患者的治疗中更具优势；度普利尤单抗可作为SEA合并慢性阻塞性肺疾病患者的首选治疗药物。

Abstract

OBJECTIVE

A clinical comprehensive evaluation of five biologic targeted drugs for the treatment of severe eosinophilic asthma （SEA） was conducted to provide objective evidence for the rational selection of these medications in medical institutions.

METHODS

Using the evaluation methods from the

Chinese Medical Institution Drug Evaluation and Selection Rapid Guide

（

Third Edition

）， the effectiveness， safety， pharmaceutical characteristics， cost-effectiveness， and other attributes of five biologics targeting SEA （omalizumab， mepolizumab， benralizumab， dupilumab， and tezepelumab） already marketed in China were quantitatively scored across five dimensions， and their recommendation levels were categorized based on the scores.

RESULTS

The comprehensive scoring results showed that mepolizumab scored 81.29， making it a highly recommended variety； benralizumab scored 78.05， dupilumab scored 77.84 and omalizumab scored 70.14，all of which are recommended varieties； tezepelumab scored 67.77， considered weakly recommended variety.

CONCLUSIONS

Mepolizumab shows excellent performance in eosinophil clearance， good accessibility， and is more cost-effective than the others， making it more selective in SEA treatment； omalizumab has more advantages in the treatment of SEA patients with elevated immunoglobulin E levels； dupilumab can be used as the preferred treatment for SEA patients with chronic obstructive pulmonary disease.

关键词

Keywords

references

Global Initiative for Asthma . Global strategy for asthma management and prevention，2025 [EB/OL ] .（ 2025-05-06 ） [ 2025-06-06 ] . https：//ginasthma.org/2025-gina-strategy-report https://ginasthma.org/2025-gina-strategy-report .

中国医药教育协会慢性气道疾病专业委员会，中国哮喘联盟 . 重度哮喘诊断与处理中国专家共识：2024 [J ] . 中华医学杂志， 2024 ， 104 （ 20 ）： 1759 - 1789 .

郭秦星，刘婉莹，姚欣 . 重症哮喘的治疗进展 [J ] . 中国临床研究， 2023 ， 36 （ 4 ）： 487 - 491 .

赵志刚，董占军，刘建平 . 中国医疗机构药品评价与遴选快速指南：第三版 [J ] . 医药导报， 2026 ， 45 （ 1 ）： 1 - 9 .

Hanania N A ， Wenzel S ， Rosén K ， et al . Exploring the effects of omalizumab in allergic asthma [J ] . Am J Respir Crit Care Med ， 2013 ， 187 （ 8 ）： 804 - 811 .

Ortega H G ， Liu M C ， Pavord I D ， et al . Mepolizumab treatment in patients with severe eosinophilic asthma [J ] . N Engl J Med ， 2014 ， 371 （ 13 ）： 1198 - 1207 .

Lai K F ， Sun D ， Dai R ， et al . Benralizumab efficacy and safety in severe asthma：a randomized trial in Asia [J ] . Respir Med ， 2024 ， 229 ： 107611 .

Wechsler M E ， Ford L B ， Maspero J F ， et al . Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma （TRAVERSE）：an open-label extension study [J ] . Lancet Respir Med ， 2022 ， 10 （ 1 ）： 11 - 25 .

Corren J ， Pham T H ， Garcia Gil E ， et al . Baseline type 2 biomarker levels and response to tezepelumab in severe asthma [J ] . Allergy ， 2022 ， 77 （ 6 ）： 1786 - 1796 .

谢佳星，赖克方 . 重视嗜酸性粒细胞性重度哮喘的治疗 [J ] . 国际呼吸杂志， 2025 ， 45 （ 8 ）： 670 - 680 .

Bourdin A ， Husereau D ， Molinari N ， et al . Matching-adjusted comparison of oral corticosteroid reduction in asthma：systematic review of biologics [J ] . Clin Exp Allergy ， 2020 ， 50 （ 4 ）： 442 - 452 .

Basagaña M ， Martínez-Rivera C ， Padró C ， et al . Clinical characteristics of complete responders versus non-complete responders to omalizumab，benralizumab and mepolizumab in patients with severe asthma：a long-term retrospective analysis [J ] . Ann Med ， 2024 ， 56 （ 1 ）： 2317356 .

Chapman K R ， Albers F C ， Chipps B ， et al . The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma [J ] . Allergy ， 2019 ， 74 （ 9 ）： 1716 - 1726 .

Jackson D J ， Burhan H ， Menzies-Gow A ， et al . Benralizumab effectiveness in severe asthma is independent of previous biologic use [J ] . J Allergy Clin Immunol Pract ， 2022 ， 10 （ 6 ）： 1534 - 1544.e4 .

Gates J ， Hearn A ， Mason T ， et al . Long-term effectiveness of anti-IL-4R therapy following suboptimal response to anti-IL-5/5R therapy in severe eosinophilic asthma [J ] . J Allergy Clin Immunol Pract ， 2024 ， 12 （ 7 ）： 1794 - 1800 .

Kavanagh J E ， Hearn A P ， Dhariwal J ， et al . Real-world effectiveness of benralizumab in severe eosinophilic asthma [J ] . Chest ， 2021 ， 159 （ 2 ）： 496 - 506 .

Ando K ， Fukuda Y ， Tanaka A ， et al . Comparative efficacy and safety of tezepelumab and other biologics in patients with inadequately controlled asthma according to thresholds of type 2 inflammatory biomarkers：a systematic review and network meta-analysis [J ] . Cells ， 2022 ， 11 （ 5 ）： 819 .

Chan R ， Stewart K ， Misirovs R ， et al . Targeting downstream type 2 cytokines or upstream epithelial alarmins for severe asthma [J ] . J Allergy Clin Immunol Pract ， 2022 ， 10 （ 6 ）： 1497 - 1505 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical comprehensive evaluation of four Chinese patent medicines in the treatment of hyperlipidemia

Clinical comprehensive evaluation of 16 commonly used kinds of enteral nutrition preparations in Hebei province

Clinical comprehensive evaluation of five marketed thrombopoietin receptor agonists in China

Clinical comprehensive evaluation of desloratadine in the treatment of urticaria

Research about clinical comprehensive evaluation methods of pediatric drugs ：taking pediatric anti-allergic drugs as an example

Related Author

SONG Jinfang

ZHENG Lei

TANG Xianshuai

QIN Yizhuo

ZHANG Mingzhu

GAO Yuan

ZHANG Zhihan

CHENG Yue

Related Institution

Dept. of Pharmacy， Shandong Provincial Third Hospital Affiliated to Shandong University

Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy， Xuzhou Medical University

Dept. of Pharmacy， the Affiliated Hospital of Jiangnan University

Dept. of Clinical Nutrition， the Fourth Hospital of Hebei Medical University

Dept. of Clinical Nutrition， Hebei General Hospital

⁰